Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends in the Biotech Sector: A Comparative Analysis

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Bio-Techne Corporation and Agios Pharmaceuticals, Inc., from 2014 to 2023.

Bio-Techne Corporation: A Steady Climb

Bio-Techne Corporation has shown a consistent upward trajectory in SG&A expenses, reflecting a strategic expansion. From 2014 to 2023, their expenses surged by over 500%, peaking at approximately $378 million in 2023. This growth underscores Bio-Techne's commitment to scaling operations and enhancing market presence.

Agios Pharmaceuticals, Inc.: A Volatile Journey

Agios Pharmaceuticals, Inc. experienced a more volatile pattern. Their SG&A expenses increased by over 500% from 2014 to 2020, reaching a high of around $149 million. However, post-2020, expenses stabilized, indicating a shift towards operational efficiency.

This comparative analysis highlights the diverse financial strategies within the biotech sector, offering valuable insights for potential investors.